As of data published in October 2022, the BA.4/5 bivalent Omicron-containing vaccine mRNA-1273.214 (Moderna) induced better neutralizing antibody responses against Omicron than the original ancestral mRNA-1273 vaccine. The bivalent booster also elicited higher binding antibody responses against Alpha, Beta, Gamma, and Delta. In addition, the bivalent vaccine that targets the original virus and the Omicron variant has proven superior to the original booster regardless of age and previous SARS-CoV-2 infection status.
In the EU, there are now multiple bivalent Omicron-containing vaccines available that target the original strain plus either Omicron BA.1 or Omicron BA.4-5 for people aged ≥ 12 years who have received at least primary vaccination against COVID-19.
Learn more about COVID-19 vaccines.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Michael Stuart Bronze. Fast Five Quiz: COVID-19 Prevention - Medscape - Dec 16, 2022.